Kroll, a global leader in risk and financial advisory solutions, has unveiled findings from its recent "State of Cyber Defense: Diagnosing Cyber Threats in Healthcare" report. This study highlights a significant disparity between perceived and actual cybersecurity maturity within the healthcare sector. The report finds that while nearly half of the healthcare businesses surveyed consider their cybersecurity processes to be "very mature," in reality, only 3% possess truly mature cyber processes ..read more

Any given human blood sample has 15,000 small biological molecules that can give precise information about a person’s health at any given time. However, less than 5% of these molecules are known and can be identified. The team at Isospec Analytics has developed a breakthrough biomolecular analysis technology that identifies unknown molecules at scale for pharmaceutical, agritech and nutrition companies ..read more

Report highlights: We are currently at an exciting juncture where several big pharmaceutical companies have started adopting such models and conducted several exploratory studies The last 4 years have witnessed at least twofold increase in industrial validation of organ-on-chips across various fields and organ models The majority of the studies can be broadly categorized under ADME&T (ADME & toxicity) (55.7%) followed by disease modeling on chips (30%) The rigorous industrial testing and strong backing from regulatory agencies indicate, the next 3-5 years can be a favorable inv ..read more

Seed Health has announced the launch of CODA, a cutting-edge computational biology platform that utilizes the extensive data from the Human Phenotype Project. This project, led by Professor Eran Segal from the Weizmann Institute of Science, boasts the world’s most comprehensive multi-omics data set. CODA is designed to harness this data to forge new paths in the development of precision probiotics and microbiome-directed interventions, with initial focus areas including cardiometabolic health, brain health, menopause, and longevity ..read more

My interview with Mirit Eldor, Managing Director, Life Sciences Solutions, at Elsevier, as we discuss Elsevier's recent collaboration with gen AI company Iktos and broader efforts ..read more

Fierce competition. Thin pipelines. Patent cliffs. The stakes are sky-high for pharmaceutical companies and investors alike. With biotech firms often going public before generating revenue, valuations hinge on the potential for FDA approval of their assets. Herein lies the power of artificial intelligence (AI): by predicting the likelihood of success for these assets, we can uncover undervalued companies, offering a strategic edge not only to hedge funds and VCs but also to big pharma companies considering acquisitions. In this dynamic landscape, projected to see M&A activities reaching as ..read more

In a detailed interview, Dr. Brian Jamieson, founder and CTO of Diagnostic Biochips (DBC), delves into the evolving landscape of brain-computer interfaces (BCIs), a domain where the fusion of neuroscience and cutting-edge technology is opening new avenues for human-computer interaction ..read more

In a collaborative effort between Brainomix, an AI-powered medical technology company, and AstraZeneca, a new study demonstrates significant advancements in the identification and stratification of patients with idiopathic pulmonary fibrosis (IPF) at risk of disease progression. The research, published in the American Journal of Respiratory and Critical Care Medicine, leveraged Brainomix's e-Lung software, a cutting-edge artificial intelligence-enabled tool designed for automated processing of CT scans in clinical settings ..read more

The biotech industry is experiencing a big wave of investment, similar to the high levels seen between 2020 and 2021.  In just the last three months, there's been a rush of big money deals, with companies like Engrail Tx, Clasp Tx, Capstan Tx, and Mirador Tx announcing large funding amounts of $157 million, $150 million, $175 million, and $400 million, respectively.  Since the beginning of the year, 22 biotech startups have raised over $100 million each (see table below).  Investors are showing interest in companies that are close to or in the middle of clinical trials, whi ..read more

NVIDIA's CEO, Jensen Huang, recently outlined the company's expanded focus on software solutions designed to facilitate the adoption of artificial intelligence (AI) in the biopharmaceutical sector, beyond its well-established position as a leading hardware manufacturer. As Endpoints News reports, during a keynote speech at the annual NVIDIA developer's conference, held at the SAP Center in San Jose, California, Huang highlighted the pivotal role of healthcare in what he described as a new industrial revolution powered by generative AI ..read more